| 杨 黎,李万成,杨 丹,朱彦锋,冯晓丽.益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂对COPD稳定期患者肺功能、细胞免疫功能和血清bFGF、SIRT1的影响[J].现代生物医学进展英文版,2023,(20):3908-3912. |
| 益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂对COPD稳定期患者肺功能、细胞免疫功能和血清bFGF、SIRT1的影响 |
| Effect of Yifei Capsule and Umeclidinium Bromide and Vilanterol Powder for Inhalation on Lung Function, Cellular Immune Functio and Serum bFGF, SIRT1 in Patients with COPD at Stable Stage |
| Received:March 24, 2023 Revised:April 20, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.20.022 |
| 中文关键词: COPD 稳定期 益肺胶囊 乌美溴铵维兰特罗吸入粉雾剂 肺功能 细胞免疫功能 bFGF SIRT1 |
| 英文关键词: COPD Stable stage Yifei capsule Umeclidinium bromide and vilanterol powder for inhalation Lung function Cellular immune function bFGF SIRT1 |
| 基金项目:成都医学院第一附属医院科研项目国家临床培训专项（CYFY2018GLPHX06）；四川省科技厅应用基础项目（2022NSFSC0725） |
|
| Hits: 415 |
| Download times: 298 |
| 中文摘要: |
| 摘要 目的：探讨益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂对慢性阻塞性肺疾病（COPD）疾病稳定期患者肺功能、细胞免疫功能和血清碱性成纤维细胞生长因子（bFGF）、沉默信息调节因子1（SIRT1）的影响。方法：纳入我院2021年3月~2022年6月期间收治的COPD稳定期患者104例，按照随机数字表法分为对照组（乌美溴铵维兰特罗吸入粉雾剂治疗，n=52）和观察组（益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂治疗，n=52）。对比两组临床症状恢复时间、6 min步行试验（6MWT）和COPD评估测试（CAT）评分、肺功能[第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、每分钟最大通气量（MVV）]、细胞免疫功能和血清bFGF、SIRT1水平，观察两组不良反应发生情况。结果：与对照组相比，观察组的肺啰音、咳嗽、咯痰消失时间缩短（P<0.05）。与对照组相比，观察组治疗14 d后6MWT更远，CAT评分更低（P<0.05）。与对照组相比，观察组治疗14 d后FVC、FEV1、MVV更高（P<0.05）。与对照组相比，观察组治疗14 d后CD3+、CD4+、CD4+/CD8+更高，CD8+更低（P<0.05）。与对照组相比，观察组治疗14 d后bFGF更低，SIRT1更高（P<0.05）。两组不良反应总发生率组间对比无差异（P>0.05）。结论：益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂有助于调节COPD稳定期患者血清bFGF、SIRT1水平，改善肺功能和细胞免疫功能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Yifei capsule combined with umeclidinium bromide and vilanterol powder for inhalation on lung function, cellular immune function, serum basic fibroblast growth factor (bFGF) and silent information regulator 1 (SIRT1) in patients with chronic obstructive pulmonary disease (COPD) at stable stage. Methods: 104 patients with COPD at stable stage who were admitted to our hospital from March 2021 to June 2022 were select and they were divided into control group (treatment with umeclidinium bromide and vilanterol powder for inhalation, n=52) and observation group (treatment with Yifei capsule combined with umeclidinium bromide and vilanterol powder for inhalation, n=52) according to random number table method. Clinical symptom recovery time, 6min walking test (6MWT) and COPD assessment test (CAT) score, lung function [forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), maximum gas volume per minute (MVV)], cellular immune function and serum bFGF and SIRT1 levels in the two groups were compared. The occurrence rate of adverse reactions in the two groups was observed. Results: Compared with the control group, the disappearance time of lung rales, cough and sputum in the observation group were shortened (P<0.05). Compared with the control group, the 6MWT in the observation group at 14 d after treatment was longer, and the CAT score was lower (P<0.05). Compared with the control group, FVC, FEV1 and MVV in the observation group at 14 d after treatment were higher (P<0.05). Compared with the control group, CD3+, CD4+, CD4+/CD8+ in the observation group at 14 d after treatment were higher, and CD8+ was lower (P<0.05). Compared with the control group, bFGF in the observation group at 14 d after treatment was lower, and SIRT1 was higher (P<0.05). There was no difference in the total incidence rate of adverse reactions in the two groups (P>0.05). Conclusion: Yifei capsule combined with umeclidinium bromide and vilanterol powder for inhalation can help regulate serum bFGF and SIRT1 levels in patients with COPD at stable stage, and improve lung function and cellular immune function. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
